A practical reference on lipodystrophy: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-02 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
Once reconstituted, the peptide is handled as a solution and is less stable than the lyophilized powder. Aqueous solutions are commonly kept cold and used within a defined period. Buffer composition and pH influence degradation rates, with extremes of acidity or alkalinity accelerating hydrolysis. Preservatives may be added in multi-dose formats to limit microbial growth. Freezing and thawing of solutions is generally avoided because it can cause precipitation or loss of activity.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
冻干粉末一般在 -20°C 或更低温度、干燥避光条件下保存，可维持较长时间的稳定。复溶后稳定性明显下降，溶液中的肽链易发生水解、氧化与聚集，通常需冷藏并在短期内用完。反复冻融会加速聚集与降解，建议分装后单次使用。缓冲体系的 pH 与离子强度同样影响聚集速率，需要按具体实验条件验证。
研究用与临床用材料的标准并不相同。质量控制通常覆盖纯度、残留溶剂、反离子含量、微生物限度与内毒素水平，各项均有对应检测方法。随货文件应包含批号、检测项目、方法与结果，使数据可以追溯。核验时应关注纯度是否按主峰面积计算、杂质是否已定性、方法是否经过验证，这些信息决定结果能否被外部重复。
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
== Management == Red ear syndrome has proven difficult to treat. The most widely attempted medication is gabapentin, with one case series finding that seven of eight patients on gabapentin showed improvement in attack frequency and ear color. Smaller studies have reported some success in certain patients using amitriptyline, flunarizine, imipramine, verapamil, propranolol and ibuprofen. Appropriate medication may differ depending on the underlying cause of the individual's symptoms. Using an ice pack to cool the ear during an attack can provide temporary relief.
== Industrial applications == Imidazole itself has few direct applications. It is instead a precursor to a variety of agrichemicals, including enilconazole, climbazole, clotrimazole, prochloraz, and bifonazole.
== Chemical modifications == Creating chemically stable short oligonucleotides was the earliest challenge in developing ASO therapies. Naturally occurring oligonucleotides are easily degraded by nucleases, an enzyme that cleaves nucleotides and is ample in every cell type. Short oligonucleotide sequences also have weak intrinsic binding affinities, which contributes to their degradation in vivo.
Sources: en.wikipedia.org
He consulted the weather records for 1928, and found that, as in 1966, there was a heat wave in mid-August followed by nine days of cold weather starting on 28 August that greatly favoured the growth of the mould.
== References == Blauw, H.; et al. (2020), "Clinical validation of a bihormonal artificial pancreas", Diabetes Technology & Therapeutics, vol. 22, Mary Ann Liebert, INC 140 Huguenot Street, 3RD FL, NEW ROCHELLE, NY 10801 USA, p. A36-A37
One of the first adoptions of the trope is Rachel Pollack's Tree House (1984). The titular megaflora in Larry Niven's 1984 novel The Integral Trees exist within an orbiting gaseous torus full of life adapted to free-fall. The concept is discussed in Carl Sagan and Ann Druyan's 1985 non-fiction book Comet, and several paintings of Dyson trees around Saturn and in interstellar space are provided in the book by Jon Lomberg. In Michael Swanwick's 1987 transhumanist novel Vacuum Flowers, "dysonsworlders" have established tree settlements in the Oort Cloud. Under the name of "Space Poplars", Dyson trees are described in Donald Moffitt's two science fiction novels, The Genesis Quest and Second Genesis. Here they are used as both habitats and spacecraft, propelled by reflective outer leaves used as organic solar sails. Dan Simmons, in Endymion (1996) and the Rise of Endymion (1997) – both part of his Hyperion Cantos – refers to Dyson trees, and in the latter novel to a huge tree system that surrounds an entire star (reminiscent of a Dyson sphere). In Stephen Baxter's Manifold: Space (2001), Baxter's protagonist Reid Malenfant at one point finds himself inside a Dyson tree. In the Orion's Arm shared universe (established 2000), Dyson trees and Dyson tree "forests" are called orwoods; these have been established in a number of star systems throughout terragen space. The word "Orwood" in this context was originally coined by Anders Sandberg. The Transhuman Space roleplaying game includes the beginning of a Dyson tree endeavour on Yggdrasil Station.
Sources: en.wikipedia.org
== Distribution == The principal factor controlling the distribution of aquatic plants is the availability of water. However, other abiotic factors may also control their distribution including nutrient availability, availability of carbon dioxide and oxygen, water temperature, characteristics of the substrate, water transparency, water movement, and salinity. Some aquatic plants are able to thrive in brackish, saline, and salt water. Also biotic factors like grazing, competition for light, colonization by fungi, and allelopathy are influencing the occurrence of macrophytes.
Charcot–Marie–Tooth disease (CMT; , shar-KOE ma-REE TOOTH), also known as hereditary motor and sensory neuropathy (HMSN), is an inherited neurological disorder that affects the peripheral nerves responsible for transmitting signals between the brain, spinal cord, and the rest of the body. It is the most common inherited neuropathy that causes sensory and motor symptoms of numbness, tingling, weakness and muscle atrophy, pain, and progressive foot deformities over time. In some cases, CMT also affects nerves controlling automatic bodily functions like sweating and balance. Symptoms typically start in the feet and legs before spreading to the hands and arms. While some individuals experience minimal symptoms, others may face significant physical limitations. There is no cure for CMT; however, treatments such as physical therapy, orthopedic devices, surgery, and medications can help manage symptoms and improve quality of life. CMT is caused by mutations in over 100 different genes, which disrupt the function of nerve cells' axons (responsible for transmitting signals) and their myelin sheaths (which insulate and accelerate signal transmission). When these components are damaged, nerve signal transmission slows down or becomes impaired, leading to problems with muscle control and sensory feedback. The condition was discovered in 1886 by doctors Jean-Martin Charcot and Pierre Marie of France and the English neurologist Howard Henry Tooth. This disease is the most commonly inherited peripheral neuropathy, affecting approximately one in 2,500 people.
On 29 July, TTP attacked the Khazina Banda Police checkpost in Hangu District killing nine policemen and wounding 28, while Pakistani forces claimed to have killed 15 insurgents in retaliation. while four FC soldiers were killed in a TTP attack on an FC post in the Musa Darra area of Hassankhel. IGP KP stated that militants in southern district of KP were using weapons left by NATO during withdrawal from Afghanistan. On 30 July, police forces neutralized a bomb in Muslim Bagh area near Serai Naurang of Lakki Marwat District. Pakistani forces killed a TTP militant in Bajaur District and two in Kulachi area of Dera Ismail Khan District. Insurgents also blew up a government school in Bajaur District. On 31 July, an Army Major and five TTP insurgents were killed in a military operation in Razmak, 15 Hafiz Gul Bahadur Group insurgents were killed throughout Bannu and one in Loi Mamond area of Bajaur District. Two members of Ahmadzai Aman committee were killed and seven wounded in a militant quadcopter strike in Barganto area of Bannu District while two policemen were killed in an ambush in Chodhwan area of Dera Ismail Khan. On 1 August, CTD claimed to have captured 54 suspected terrorists in 419 operations throughout Punjab, belonging to ISIS, Al Qaeda, LeJ, SSP and TTP. On 2 August, 10 civilians and seven Policemen were killed and 34 were wounded in a suicide attack on Kabal Police Station in Swat District, the attack being claimed by TTP. Pakistan blamed Afghanistan for sheltering and facilitating the perpetrators.
=== Purine catabolism === Purine degradation primarily occurs in the liver in humans and requires a series of enzymes to break down purines into uric acid. First, nucleotides lose their phosphate groups through the action of 5'-nucleotidase. The purine nucleoside adenosine is then deaminated by adenosine deaminase and hydrolyzed by a nucleosidase to form hypoxanthine. Hypoxanthine is subsequently oxidized to xanthine and then to uric acid via the enzyme xanthine oxidase. The other purine nucleoside, guanosine, is cleaved to form guanine. Guanine is then deaminated by guanine deaminase to produce xanthine, which is further converted to uric acid. In both degradation pathways, oxygen serves as the final electron acceptor. The excretion of uric acid varies among different animals. Free purine and pyrimidine bases released within the cell are often transported across membranes and salvaged through the nucleotide salvage pathway to regenerate nucleotides. For example, adenine combines with phosphoribosyl pyrophosphate (PRPP) to form adenosine monophosphate (AMP) and pyrophosphate (PPi) in a reaction catalyzed by adenine phosphoribosyltransferase. Similarly, free guanine is salvaged via a reaction requiring hypoxanthine-guanine phosphoribosyltransferase (HGPRT). Defects in purine catabolism can lead to various diseases, including gout, which results from the accumulation of uric acid crystals in joints, and adenosine deaminase deficiency, which causes immunodeficiency.
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
Refrigeration between 2 and 8 degrees Celsius is typical, with protection from moisture and light. Dry, sealed containers help maintain stability over the labeled shelf life. Temperature cycling is usually minimized.